
Domenico Penna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3881049/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clinic Proceedings, 2019, 94, 599-610.	1.4	103
2	Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. American Journal of Hematology, 2018, 93, 1474-1484.	2.0	56
3	Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. Blood Cancer Journal, 2019, 9, 12.	2.8	52
4	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. Hematological Oncology, 2018, 36, 561-569.	0.8	46
5	A prognostic model for patients with lymphoma and COVID-19: aÂmulticentre cohort study. Blood Advances, 2022, 6, 327-338.	2.5	28
6	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter studyâŽ. Seminars in Hematology, 2018, 55, 248-255.	1.8	24
7	Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels. Blood Advances, 2018, 2, 1980-1984.	2.5	13
8	SFLTâ€1 levels in COVIDâ€19 patients: Association with outcome and thrombosis. American Journal of Hematology, 2021, 96, E41-E43.	2.0	11
9	20+ Years and alive with primary myelofibrosis: Phenotypic signature of very longâ€lived patients. American Journal of Hematology, 2019, 94, 286-290.	2.0	10
10	Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. Blood Cancer Journal, 2018, 8, 118.	2.8	7
11	The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis. Blood, 2018, 132, 1761-1761.	0.6	4
12	The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, E164-E167.	2.0	1
13	Genetic predictors of response to specific drugs in primary myelofibrosis. Blood Cancer Journal, 2018, 8, 120.	2.8	1
14	Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies. Leukemia, 2019, 33, 2522-2553.	3.3	1
15	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Blood, 2018, 132, 3035-3035.	0.6	1
16	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. Blood, 2018, 132, 3040-3040.	0.6	1
17	Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis. Blood, 2018, 132, 4300-4300.	0.6	0
18	Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates. Blood, 2018, 132, 3034-3034.	0.6	0

#	Article	IF	CITATIONS
19	Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger. Blood, 2018, 132, 3033-3033.	0.6	о
20	Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. Blood, 2018, 132, 3044-3044.	0.6	0